论文部分内容阅读
目的研究单药苯巴比妥(PB)治疗癫(Epilepsy,EP)患者的血清免疫球蛋白含量变化。方法采用免疫比浊法测定48例单药PB抗癫治疗EP患者及30例健康对照组的血清免疫球蛋白含量。结果健康对照组IgAI、gGI、gM含量分别为2.00±0.441、2.80±2.011、.56±0.28(g/L),单药PB抗癫治疗EP患者IgA、IgGI、gM含量分别为1.08±0.69、14.33±2.66、1.44±0.22(g/L),EP患者组IgA含量低于健康对照组(P<0.01),IgG含量高于健康对照组(P<0.05),IgM含量与健康对照组没有显著差异(P>0.05)。结论单药苯巴比妥抗癫治疗EP患者IgA含量下降可能与服用苯巴比妥相关,而与病史长短及发作类型无明显相关(P>0.05)。
Objective To study the changes of serum immunoglobulin in patients with epilepsy (EP) treated with monobactam (PB). Methods Immunoglobulin was used to measure the serum immunoglobulin levels in 48 patients with EP and 48 healthy controls. Results The contents of IgA, gGI and gM in healthy controls were 2.00 ± 0.441, 2.80 ± 2.011 and 56 ± 0.28, respectively. The levels of IgA, IgGI and gM in EP patients treated with monotherapy with PB anti-epilepsy were 1.08 ± 0.69 , 14.33 ± 2.66 and 1.44 ± 0.22 (g / L) respectively. The level of IgA in EP group was lower than that in healthy control group (P <0.01), and the level of IgG in group EP was higher than that in healthy control group Significant difference (P> 0.05). Conclusions The decrease of IgA level in EP patients treated with phenobarbital antiepileptic may be related to taking phenobarbital, but not with the length of history and type of attack (P> 0.05).